Join Growin Stock Community!
Back to LLY.US Analysis
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

revenue-breakdown-chart

LLY Revenue by Segments

Revenue by Segments

Browsing restrictions can be lifted for a fee.

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

As of Q3'25, Eli Lilly's total revenue reached its highest level in the period, with Cardiometabolic Health contributing 13.18B USD, Oncology 2.41B USD, Immunology 1.36B USD, Neuroscience 316M USD, and Other segments 337M USD. Cardiometabolic Health remains the dominant segment, accounting for the majority of overall revenue in the latest quarter. From Q4'22 to Q3'25, the chart shows a strong upward trend in total revenue, primarily driven by substantial growth in Cardiometabolic Health, which more than tripled over the period. Oncology and Immunology segments also experienced moderate increases, while Neuroscience and Other segments remained relatively stable with minor fluctuations. The stacked bar chart highlights Cardiometabolic Health's expanding share, underscoring its growing importance in Eli Lilly's revenue composition over the last three years.